Trial
NCT01849887
Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of California, Irvine
Collaborators
—
Condition
Ischemic Stroke
Intervention
bone marrow-derived mesenchymal stem cells
Why stopped
Study was never started
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-22